论文部分内容阅读
目的 评价重组人表皮生长因子 (rhEGF)治疗放射性粘膜及皮肤损伤的效果。方法 88例Ⅲ级放射损伤病人中有 5 4例粘膜损伤 ,3 4例为皮肤损伤 ,均被随机分入重组人表皮生长因子治疗组与对照组 ,比较两组疼痛减轻及损伤修复速度。结果 重组人表皮生长因子治疗组疼痛缓解及损伤愈合时间均较对照组短 ,未见明显不良反应。结论 重组人表皮生长因子对放疗损伤有明显的减轻疼痛及促进愈合作用。
Objective To evaluate the effect of recombinant human epidermal growth factor (rhEGF) on radiation mucosa and skin lesions. Methods A total of 88 patients with grade Ⅲ radiation injury had mucosal injury and 34 cases with skin injury. All patients were randomly divided into recombinant human epidermal growth factor group and control group. The pain relief and the rate of injury repair were compared between the two groups. Results The pain relief and wound healing time of the recombinant human epidermal growth factor treatment group were shorter than that of the control group, and no obvious adverse reaction was found. Conclusion Recombinant human epidermal growth factor (EGF) has obvious effect of relieving pain and promoting healing on radiation injury.